These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 23922104)
1. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. van Oosterwijk JG; van Ruler MA; Briaire-de Bruijn IH; Herpers B; Gelderblom H; van de Water B; Bovée JV Br J Cancer; 2013 Sep; 109(5):1214-22. PubMed ID: 23922104 [TBL] [Abstract][Full Text] [Related]
2. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Schrage YM; Briaire-de Bruijn IH; de Miranda NF; van Oosterwijk J; Taminiau AH; van Wezel T; Hogendoorn PC; Bovée JV Cancer Res; 2009 Aug; 69(15):6216-22. PubMed ID: 19602594 [TBL] [Abstract][Full Text] [Related]
3. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Pichot CS; Hartig SM; Xia L; Arvanitis C; Monisvais D; Lee FY; Frost JA; Corey SJ Br J Cancer; 2009 Jul; 101(1):38-47. PubMed ID: 19513066 [TBL] [Abstract][Full Text] [Related]
4. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938 [TBL] [Abstract][Full Text] [Related]
5. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602 [TBL] [Abstract][Full Text] [Related]
6. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409 [TBL] [Abstract][Full Text] [Related]
7. No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone. Peterse EF; Cleven AH; De Jong Y; Briaire-de Bruijn I; Fletcher JA; Danen EH; Cleton-Jansen AM; Bovée JV BMC Cancer; 2016 Jul; 16():475. PubMed ID: 27418340 [TBL] [Abstract][Full Text] [Related]
8. SRC signaling is crucial in the growth of synovial sarcoma cells. Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575 [TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. Eustace AJ; Crown J; Clynes M; O'Donovan N J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558 [TBL] [Abstract][Full Text] [Related]
10. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Lu KV; Zhu S; Cvrljevic A; Huang TT; Sarkaria S; Ahkavan D; Dang J; Dinca EB; Plaisier SB; Oderberg I; Lee Y; Chen Z; Caldwell JS; Xie Y; Loo JA; Seligson D; Chakravari A; Lee FY; Weinmann R; Cloughesy TF; Nelson SF; Bergers G; Graeber T; Furnari FB; James CD; Cavenee WK; Johns TG; Mischel PS Cancer Res; 2009 Sep; 69(17):6889-98. PubMed ID: 19690143 [TBL] [Abstract][Full Text] [Related]
11. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. McCaig AM; Cosimo E; Leach MT; Michie AM Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196 [TBL] [Abstract][Full Text] [Related]
12. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib. Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967 [TBL] [Abstract][Full Text] [Related]
14. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells. Kim EM; Mueller K; Gartner E; Boerner J J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511 [TBL] [Abstract][Full Text] [Related]
15. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143 [TBL] [Abstract][Full Text] [Related]
17. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659 [TBL] [Abstract][Full Text] [Related]
18. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells. Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776 [TBL] [Abstract][Full Text] [Related]
19. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Nagaraj NS; Washington MK; Merchant NB Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529 [TBL] [Abstract][Full Text] [Related]
20. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]